Although it is well documented that adolescents and young adults (AYAs) with cancer have low participation in cancer clinical trials (CCTs), the underlying reasons are not well understood. We used the National Cancer Institute Community Oncology Research Program (NCORP) network to identify barriers and facilitators to AYA CCT enrollment, and strategies to improve enrollment at community-based and minority and/or underserved sites. We performed one-on-one semistructured qualitative interviews with stakeholders (NCORP site principle investigators, NCORP administrators, physicians involved in enrollment, lead clinical research associates or clinical research nurses, nurse navigators, regulatory research associates, patient advocates) in the AY...
In the United States, 1.2 million Americans are diagnosed with cancer annually and only 2.5% of adul...
Purpose: Adolescents and young adults (AYAs) aged 15-39 at diagnosis have very low cancer clinical t...
BACKGROUNDPoor accrual to cancer clinical trials may contribute to the lower improvement in survival...
Few studies have explored interventions to improve adolescent and young adult (AYA) cancer care deli...
BackgroundAdolescent and young adult (AYA) patients with cancer are underrepresented on cancer clini...
PurposeStagnant outcomes for adolescents and young adults (AYAs; 15 to 39 years old) with cancer are...
BackgroundFew adolescents and young adults (AYAs, 15-39 years old) enroll onto cancer clinical ...
PurposeClinical trial participation leads to progress in cancer care. Principal investigators (PIs) ...
Survival among adolescents and young adults (AYAs) ages 15 to 39 with cancer has not improved to the...
2018-08-08Cancer is the leading cause of disease-related death for adolescents and young adults (AYA...
Purpose: Clinical trial enrollment is low among adolescents and young adults (AYAs) with cancer and ...
Brian D Friend,1 Abinav Baweja,2 Gary Schiller,3 Jonathan Bergman,4 Mark S Litwin,4 Jonathan W Goldm...
ARST1321, a trial of patients with advanced soft tissue sarcoma, was the first National Clinical Tri...
ARST1321, a trial of patients with advanced soft tissue sarcoma, was the first National Clinical Tri...
Purpose of the studyAdolescent and young adult (AYA) cancer patients are underrepresented in clinica...
In the United States, 1.2 million Americans are diagnosed with cancer annually and only 2.5% of adul...
Purpose: Adolescents and young adults (AYAs) aged 15-39 at diagnosis have very low cancer clinical t...
BACKGROUNDPoor accrual to cancer clinical trials may contribute to the lower improvement in survival...
Few studies have explored interventions to improve adolescent and young adult (AYA) cancer care deli...
BackgroundAdolescent and young adult (AYA) patients with cancer are underrepresented on cancer clini...
PurposeStagnant outcomes for adolescents and young adults (AYAs; 15 to 39 years old) with cancer are...
BackgroundFew adolescents and young adults (AYAs, 15-39 years old) enroll onto cancer clinical ...
PurposeClinical trial participation leads to progress in cancer care. Principal investigators (PIs) ...
Survival among adolescents and young adults (AYAs) ages 15 to 39 with cancer has not improved to the...
2018-08-08Cancer is the leading cause of disease-related death for adolescents and young adults (AYA...
Purpose: Clinical trial enrollment is low among adolescents and young adults (AYAs) with cancer and ...
Brian D Friend,1 Abinav Baweja,2 Gary Schiller,3 Jonathan Bergman,4 Mark S Litwin,4 Jonathan W Goldm...
ARST1321, a trial of patients with advanced soft tissue sarcoma, was the first National Clinical Tri...
ARST1321, a trial of patients with advanced soft tissue sarcoma, was the first National Clinical Tri...
Purpose of the studyAdolescent and young adult (AYA) cancer patients are underrepresented in clinica...
In the United States, 1.2 million Americans are diagnosed with cancer annually and only 2.5% of adul...
Purpose: Adolescents and young adults (AYAs) aged 15-39 at diagnosis have very low cancer clinical t...
BACKGROUNDPoor accrual to cancer clinical trials may contribute to the lower improvement in survival...